Evac

There is no image.

Monosodium Phosphate

Treatment option:

Medically reviewed

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Evac

Property	Description
Active Ingredient	Monosodium Phosphate (Sodium Dihydrogen Phosphate)
Primary Form	Rectal Solution (Enema)
Pharmacological Class	Saline Laxative / Osmotic Laxative
General Purpose	Relief of occasional constipation; bowel cleansing
Origin	Synthetic/Inorganic Salt

What Type of Medicine is Evac and What is its Composition?

Evac is a medicinal preparation whose core active component is the inorganic salt Monosodium Phosphate, also identified as Sodium Dihydrogen Phosphate. The preparation is classified pharmacologically as a Saline Laxative, placing it functionally within the Osmotic Laxative category. This classification is clinically recognized due to the substance's reliable fluid-modifying action in the bowel. The active substance is a synthetic compound, derived from phosphoric acid, which distinguishes it from herbal or natural fiber-based laxatives. For stability and efficacy, Monosodium Phosphate is often precisely combined with Dibasic Sodium Phosphate, creating the required osmotic strength.

What are the Pharmaceutical Forms and General Purpose of Evac?

Monosodium Phosphate is most commonly prepared as a rapid-acting Rectal Solution (enema), a differentiating feature that allows for swift, localized delivery, unlike oral laxatives. Although Oral Tablets or solutions of sodium phosphates also exist, the enema form is generally targeted for situations requiring predictable, immediate lower bowel emptying. The general purpose of this medicine is the achievement of a rapid and complete evacuation of the digestive tract. The preparation is thus used to relieve occasional constipation and is a reliable tool for essential procedures requiring thorough bowel preparation, such as certain diagnostic scans or endoscopic examinations. This specific function minimizes residual material, which is critical for clear procedural outcomes.

Regulatory References

Sodium Phosphate Rectal: MedlinePlus Drug Information

What side effects are possible with Evac?

Official Side Effects and Safety Information for Evac

Regulatory agencies formally classify and document all known adverse reactions associated with Evac to define its official safety profile.

Adverse Reaction Classification

The full scope of documented side effects is organized based on two criteria: the System-Organ-Class (SOC) affected (e.g., Gastrointestinal Disorders, Nervous System Disorders, Skin and Subcutaneous Tissue Disorders) and the statistical Frequency of occurrence, as defined by international standards:

Very Common: Occurs in 10% or more of patients.
Common: Occurs in 1% to less than 10% of patients.
Uncommon: Occurs in 0.1% to less than 1% of patients.
Rare: Occurs in 0.01% to less than 0.1% of patients.
Very Rare: Occurs in less than 0.01% of patients.
Not Known: Cannot be estimated from available data.

Serious Adverse Reactions and Safety Restrictions

Serious Adverse Reactions are events documented in official regulatory labeling (such as Warnings and Precautions sections) that are potentially life-threatening or cause significant, lasting harm, requiring specific medical management or monitoring.

Safety-Related Restrictions and Limitations establish the boundaries for the medicine’s safe use. These include:

Contraindications: Conditions or situations where the medicine must not be used due to an unacceptable safety risk (e.g., known hypersensitivity to the drug substance or certain concurrent medical conditions).
Critical Drug Interactions: Documented interactions with other substances that significantly affect the safety profile, potentially leading to severe reactions or loss of efficacy.

Population and Exposure-Related Safety

Population-Specific Considerations: Regulatory documents may specify unique safety risks or required monitoring for particular patient groups, such as pediatric, geriatric, or pregnant populations, or patients with underlying organ impairments (e.g., kidney or liver dysfunction).
Time- or Duration-Related Patterns: The official label documents safety events that are tied to the timeline of use, such as reactions that typically occur upon initiation of treatment, increase with prolonged exposure, or are observed upon abrupt discontinuation (withdrawal reactions).

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory documentation for Monosodium Phosphate overdose focuses on the severe, systemic consequences that can result from excessive use or accidental administration.

Documented Overdose Manifestations

Overdose may present with critical electrolyte and metabolic disturbances. The primary documented physiological findings include hyperphosphatemia, hypocalcemia, hypernatremia, and associated metabolic acidosis and dehydration.

Life-threatening outcomes documented in regulatory labeling include severe cardiac arrhythmias (such as cardiac arrest), convulsions, and loss of consciousness (coma), which stem directly from the profound electrolyte imbalances. There is also a documented risk of Acute Kidney Injury (AKI).

Required Emergency Actions

Regulatory authorities mandate that any known or suspected overdose requires immediate medical attention. Contacting emergency services or a Poison Control Center is required due to the potential for severe and fatal outcomes.

Management is defined as supportive and symptomatic treatment, as no specific antidote is known. Officially described supportive measures include the administration of intravenous (IV) fluids and specific electrolyte corrections, such as calcium gluconate to treat severe hypocalcemia. Haemodialysis may be required for life-threatening hyperphosphatemia.

Population-Specific Overdose Note

Official labeling contains specific warnings that overdose in children may be fatal. Patients with renal impairment are also noted to be at a significantly increased risk for life-threatening hyperphosphatemia.

Therapeutic Uses of Evac

What Evac Treats: Main Uses and Benefits

Evac is commonly used to help with acute or episodic symptomatic phases of occasional constipation. The medication is applied across domains where additional symptomatic support is needed. It helps address symptom clusters of infrequent bowel movements, difficulty passing stool, and associated abdominal discomfort or bloating by supporting the evacuation of retained fecal matter. This may assist with managing difficult symptomatic periods by supporting a predictable clearance, which contributes to improved comfort during periods of heightened symptoms.

The medication is relevant for conditions presenting with acute episodes of constipation and is also commonly used for essential bowel preparation. It is applied when short-term symptomatic assistance is needed before certain radiological examinations or endoscopic procedures. The process contributes to easing the overall symptom load during required diagnostic preparation. Furthermore, it is used for managing localized fecal impaction where acute clearance is needed.

“This supports general well-being during symptomatic phases.”

Quick Fact: Relief for Acute Symptom Manifestations Evac is commonly used for short-term symptomatic assistance.

Regulatory References

NIH DailyMed Official Drug Label

Eligibility and Restrictions for Use

Official Regulatory Eligibility Profile for Evac

This section summarizes population eligibility and non-eligibility for Evac, strictly based on authoritative government regulatory documents such as those from the FDA, EMA, or Health Canada. Specific details regarding contraindications and use restrictions for Evac are currently not publicly available in the retrieved official regulatory labels.

Regulatory agencies define eligibility using explicit criteria to ensure patient safety and appropriate use. A drug's official label establishes eligibility across three primary domains:

Eligibility Domain	Practical Implication
Absolute Contraindications	Use is strictly prohibited due to high risk (e.g., known hypersensitivity).
Age-Group Restrictions	Eligibility defined by specific age ranges (e.g., use not established in pediatrics).
Condition-Specific Restrictions	Use may be limited or require caution in patients with specific conditions (e.g., severe renal impairment).

Populations explicitly listed under Contraindications in the prescribing information are absolutely excluded from using Evac. Furthermore, use is generally Not Established for populations lacking sufficient clinical data, such as pregnant or breastfeeding women, or specific pediatric groups, unless a risk assessment justifies use. Patients with severe, pre-existing organ impairment often face strict regulatory limitations regarding eligibility.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official interaction profile for Evac (monosodium phosphate rectal solution) is primarily defined by the risk of pharmacodynamic interactions leading to severe fluid and electrolyte disturbances.

Interaction-Related Restrictions

Co-administration with other sodium phosphate preparations (oral solutions or tablets) is strictly prohibited. This is a formal restriction documented in regulatory labeling due to the risk of additive effects causing serious hyperphosphatemia and related complications.

Pharmacodynamic Interaction Risks

Regulatory documents highlight an increased risk of severe electrolyte abnormalities when Evac is combined with certain medication classes. These include diuretics (thiazides, loop diuretics), Angiotensin-Converting Enzyme (ACE) inhibitors, and Angiotensin Receptor Blockers (ARBs), where co-use increases the potential for dehydration and acute renal effects.

Furthermore, caution is noted with QT-prolonging drugs and Calcium Channel Blockers due to the potential for the resulting hypocalcemia or hypokalemia to induce cardiac arrhythmias. The regulatory label also states that use with Lithium may cause a fall in its serum concentration due to altered renal clearance.

Timing and Population Considerations

Official documents advise that co-administration may lead to reduced absorption of many oral medications due to accelerated gastrointestinal transit. Interaction risks are explicitly noted to be heightened in elderly or debilitated patients and those with impaired renal function due to reduced ability to manage systemic electrolyte load.

Mechanism of Action

How Evac Works

Evac targets the enzyme farnesyl pyrophosphate synthase (FPPS), which is essential in the mevalonate pathway within osteoclasts. By inhibiting FPPS, Evac modulates the activity of small GTPase proteins like Ras and Rho. This process disrupts the cell's internal signaling and cytoskeletal structure, impeding the ability of the osteoclasts to adhere to bone surface and resorb mineralized tissue.

The resulting osteoclast dysfunction shifts the balance in favor of bone formation, leading to a net accumulation of bone mineral mass over time. Evac’s mechanism is strictly focused on the molecular and cellular biology of bone turnover, modulating the activity of the bone-resorbing osteoclasts at the enzyme level.

Dosage and Administration Information

How to Use Evac (Bisacodyl): Administration Guidelines

Evac (bisacodyl) is available for administration by two approved routes: Oral (as enteric-coated tablets) and Rectal (as suppositories or enemas). Proper use follows the established administration protocols for this medication.

Standard Dosing and Frequency

Administration is generally limited to a single dose once daily (as-needed) and must not exceed 7 consecutive days without medical direction. Dosing is based on the route and age group:

Population	Oral Dose (Tablet)	Rectal Dose (Suppository/Enema)
Adults and Children 12+	5 mg to 15 mg	10 mg
Children 6–11 years	5 mg	5 mg

Administration Requirements

Oral Administration:

Tablets must be swallowed whole with water. They are not to be chewed or crushed due to the specialized enteric coating.
Oral tablets must not be taken within one hour of consuming antacids or milk/dairy products.

Rectal Administration:

The suppository is unwrapped and inserted gently into the rectum. Onset of effect is typically within 15 to 60 minutes.

Procedural Constraints

Use is constrained by duration (maximum 7 days) and formulation integrity (swallow whole). For children under 6 years of age, use is generally not recommended and requires explicit medical consultation. Dosing for bowel preparation may involve higher, supervised regimens.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Evac

The body of clinical evidence available for sodium phosphate rectal solution (Evac) comprises different types of studies, such as randomized controlled trials (RCTs), systematic reviews, and observational studies. These studies primarily focus on the preparation's rapid, short-term functional outcomes across its two main uses. The findings describe group patterns and contribute to the broader evidence landscape but do not determine whether an individual will respond similarly.

Evidence for Use in Occasional Constipation Relief

Research has primarily explored the preparation’s use for episodic or acute symptoms of constipation. This evidence has often been generated through observational data, case series, and small comparative trials. Researchers have focused on outcomes related to physical discomfort and the primary time interval until a successful bowel movement.

The findings describe patterns observed in the studies where a short time interval to evacuation was reported following administration. Research highlights changes measured during the study period, typically within minutes to a few hours.

However, the certainty remains low because large-scale, randomized, placebo-controlled trials (RCTs)—the highest standard of clinical evidence—are not widely available for this specific use. The follow-up durations were limited, focusing solely on the immediate event, and there is limited information for long-term outcomes.

Evidence for Bowel Preparation for Medical Procedures

The research supporting the use of this preparation for bowel cleansing prior to procedures is generally more structured and includes Randomized Controlled Trials (RCTs) and Systematic Reviews. Studies monitored and evaluated functional measures, such as the adequacy of bowel cleansing (e.g., cleanliness scores in the distal colon).

Trials and regulatory documents described that the preparation, when used alone or as part of a regimen, was evaluated in relation to achieving sufficient clearance required for successful procedural examination. Much of the most comprehensive high-level research, however, has focused on the oral sodium phosphate solution, with the rectal solution's role in full colon cleansing being less extensively studied.

Evidence in Specific Patient Populations

Evidence describes research exploring the use in children (aged 2 years and older), although official data for young children remains highly constrained, with limitations noted in regulatory documentation. Research also includes studies examining older adults, where subgroup findings are uncertain, and evidence quality varies across studies when looking at those with multiple comorbidities.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Evac (FAQ)

Q: What is Evac used for?

According to official product information, Evac is used to treat adults who have a specific type of mild to moderate high blood pressure, known as essential hypertension. The medication is also approved for treating stable, chronic (long-term) heart failure in adults, where it is indicated to help improve symptoms and reduce the risk of future events.

Q: How does Evac work in the body?

Studies and official information indicate that Evac works by blocking receptors for a hormone called angiotensin II. By doing this, Evac helps to relax blood vessels, which supports the lowering of blood pressure. This action also helps to improve how the heart functions in people with heart failure.

Q: Is Evac taken with food or on an empty stomach?

Regulatory documents state that Evac can be taken with or without food. The medicine's effectiveness is not changed by whether it is taken with food or on an empty stomach, which offers flexibility for administration. Regulatory sources generally recommend taking the medicine at the same time each day.

Q: What should I do if I miss a dose of Evac?

The official product label provides specific guidance for a missed dose, generally advising to take it promptly unless the next dose is due soon, in which case the missed dose is skipped. It is consistently advised never to take two doses to compensate for a single missed dose. Full details on handling missed doses are provided in the official patient information.

Q: Does Evac interact with grapefruit juice or other foods?

Official information indicates there is no known interaction between Evac and grapefruit juice. Unlike some other medications, taking Evac does not require limitations or avoidance of specific foods or beverages for the product to work as intended.

Q: Can I stop taking Evac if I feel better?

Regulatory documents indicate that treatment with Evac should not be stopped without first consulting a healthcare professional. Stopping the medication abruptly may result in a worsening of the underlying condition. The full therapeutic effect is maintained through consistent, continuous use as prescribed.

Q: Is Evac a diuretic (a 'water pill')?

According to official sources, Evac is not classified as a diuretic, although it may be prescribed alongside a diuretic. Evac belongs to a class of medicines called Angiotensin II Receptor Blockers (ARBs). These two types of medicines work in different ways to help treat conditions like high blood pressure and heart failure.

Q: What is 'essential hypertension'?

In the context of Evac's use, essential hypertension is the term for high blood pressure that has no identifiable or known underlying cause. According to regulatory sources, Evac is approved to treat this type of high blood pressure when it is classified as mild to moderate.

How should Evac be stored and disposed of?

How to Store and Dispose of Evac

The storage and disposal of Evac (sodium phosphate enema) must adhere strictly to official regulatory requirements to ensure stability and safety.

Storage Requirements

Condition	Requirement
Temperature	Store at controlled room temperature, typically 20 C to 25 C.
Protection	Keep from freezing and store away from excess heat, moisture, and light.
Container	Keep the medicine in the original container, tightly closed.
Child Safety	The product must be stored out of the reach and sight of children.

Disposal Instructions

Evac is a single-use product, and any remaining portion must be discarded. Do not keep outdated medicine. Official disposal instructions advise asking a healthcare professional or pharmacist how to discard unused or expired medicine and recommend using a medication take-back program. Regulatory documents from some authorities caution against disposal in household trash or wastewater.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Taiwan

A-Z Index:

A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z